The conference was a great success and fruitful.

Cai Bao, VP of BioManufacturing

Fantastic conference with professional team

Blue Blood Biotech
Julio Lin, VP

Informative session. Exhibition was well targeted and diverse. Presenters shared latest development

Hillman Laboratories
Sankar Dharmaraj, Head, GMP Operations

It was an awesome experience to interact with so many energetic young professionals around the globe and share technical information. I want to express my heartfelt gratitude to the organizer for such a great event!

MD Atiqur Rahman, Senior Executive Officer, Professional (Sterile)

It was great to attend the session physically, and have some exchange with industry players and exchange ideas. Thanks IMAPAC for great organisation!

KOH WEI JET, EVF Project Process Manufacturing Leader

Great forum for face to face interactions and for exchange of ideas and information.

WuXi Biologics
Chris Lee, Site Head, Singapore Development and Manufacturing

The entire event was managed flawlessly by the Organizers. I personally did not face any technical glitches despite this even was organized in a hybrid manner. Almost every speaker gave a high quality presentation which was very insightful.

Lupin Ltd
Chandrakant Kathote, Site Head and Vice President

It was really great experience for me to be associated with IMAPAC which organizes high standard conference. Speakers from various domains/fields are thoughtfully chosen & they have delivered the relevant fields of present post-covid pandemic biologics scenario.

Serum Institute of India Pvt. Limited
Dr. Swapan Kumar Jana, Director-R&D and Manufacturing

A well organized ambitious meeting. I hope it will continue to develop in the future.

GSK Vaccines
Jean-Francois Dierick, Strategic Analytical Validation and Lifecycle Lead, Analytical Research and Development

This conference was long overdue in Singapore and critical to making sure that CCT understands current challenges facing our Asian based clients. This allows us to quickly provide new or turn-key solutions and products that meet their needs.

Cold Chain Technologies
Regional Commercial Director

BMA 2022 was an excellently organised event and as a sponsor, participating was very valuable in meeting new connections and engaging with existing customers & contacts. I would recommend anyone involved in the regional biologics industry to participate in the event.

Ciaran O'Keeffe, Director, Business Development & Channel Sales

With the many restrictions and the need to hold the event onsite and online, I do think this event is well planned and held. Easy registration. Spacious, simple and professional settings. All the staffs are very friendly and helpful too. Thank you!

West Pharmaceutical Services
Sr. Technical Account Specialist

Bioworkshops appreciate the effort IMAPAC invested to restore a strong In-person participation to this hybrid event, bringing together many of the biologics manufacturing leaders from Asia along and global experts.

Bioworkshops Limited
Nick Kotlarski, President, VP of BioManufacturing
In-Person Networking Hours
Case Studies
The Concept

With USD 9.9 million investment in new biopharmaceutical production facilities in Ireland over the previous ten years for new biotech manufacturing facilities, Ireland has recently become a place of choice for biopharmaceutical manufacturing. There are manufacturing facilities here for nine of the top ten pharmaceutical firms in the world, including Novartis, AbbVie, Janssen, Pfizer, Sanofi, GlaxoSmithKline, MSD, Bristol-Myers Squibb, and Takeda.

For instance, AstraZeneca invested USD 64 million on Irish manufacturing and R&D growth in June 2022; this will increase Alexion's capacity to produce drug substances in Ireland. The manufacturing facility for Johnson & Johnson in Ringaskiddy, Ireland finished a USD 354 million expansion, and now it has plans to increase the site's capacity even further. At its facility in Cork, Merck kGaA will invest more than USD 421 million in May 2022 to increase its production capabilities for membrane and filtering. Additionally, Takeda is establishing a single-use facility for the company's rare disease portfolio, MSD is building a facility to manufacture Keytruda, and BMS will manufacture its immuno-oncology drugs at a new USD 900 million plant in Dublin.

There are no indicators that investment in Ireland's biomanufacturing industry will decrease. The country's existing businesses are expanding their facilities, and new businesses are trying to establish themselves on the Emerald Isle. One such company is WuXi Biologics from China, which intends to construct the largest single-use manufacturing facility in the world in Dundalk, Ireland, as a new vaccine manufacturing facility.

Ireland’s strength in the bio manufacturing sector is down to a number of factors, and, whilst tax incentives are important, they are not the ultimate factor. The pharma industry is a prime example of what Moran refers to as the "knowledge-based sector," which was the focus of government expenditure and initiatives. Consider the Irish government's funding of the University College Dublin-based National Institute for Bioprocessing Research & Training (NIBRT). It is currently one of the top institutions in the world for training courses to support sophisticated biomanufacturing procedures.

IDA Ireland anticipates ongoing investment in 2021 despite the epidemic. The organization is starting a new "Strategy 2021-2024" with a focus on five pillars: growth, transformation, regions, sustainability, and impact. This strategy aims to attract 800 investments and create 50,000 new employment. The Irish government is devoted to keeping up its investments in research and education to make sure that Ireland continues to be a popular choice for new biotechnology manufacturing enterprises.

Download Brochure
Agenda At A Glance

Ireland Biomanufacturing Summit 2024 provides the platform for senior decision-makers who will influence the future of Ireland’s biologics manufacturing industry. Ireland and international biopharmas, big pharmas, CMOs, academic & research institutes, and solution providers will convene to discuss strategic issues, leverage partnerships, share best practices, and capitalize on the potential of Ireland’s growing biologics manufacturing industry.

In addition, this year, speakers will be exploring must-see innovations from Ireland, upstream process optimization, speed up downstream process, cost reduction, process optimization strategies to maintain competitiveness as well as understand the flexibility in biopharmaceutical manufacturing capacity.

Plenary Session:

Why Ireland for Biologics Manufacturing?

Latest Updates about Ireland Biologics Plant Expansion

Upstream Processing:

Advances in Cell Line Development & Cell Culture Media Development

Upstream Processing:

Process Intensification & Perfusion

Downstream Processing:

Late-Stage Process Development & Viral Clearance

Downstream Processing, Analytics & Quality:

Digitalization of Process Control, Robustness and Monitoring

Facility Design, Tech Transfer & Scale Up Strategy:

Flexibility in Biologicsl Manufacturing Capacity

Emerging Technologies and Applications:

Advanced Biologics Manufacturing Techniques

Download Brochure
Tickets On Sale, Catch The Deal Now To SAVE BIG!!

Limited Super - End User

SGD 1595
  • 2- Day Conference Access
  • Valid Until 25th November 2022
  • Full Price SGD 2195

Limited Super - Vendor

SGD 3295
  • 2- Day Conference Access
  • Valid Until 18th November 2022
  • Full Price SGD 3895
Meet Your Sales & Marketing Objectives - Partner With Us Today!
Thought Leadership

Present your expertise to the Asian Bioprocessing industry’s key stakeholders through a variety of available speaking packages.


Join the exhibition, and build an impressive presence among your potential clients.


Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.


Engage with and build lasting connections that matter the most to your business.

Lead Generation

Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.